Navigation Links
SemBioSys submits IND for safflower-produced insulin to U.S. FDA
Date:7/29/2008

ntends to conduct a Phase I/II trial in the UK. The CTA requests approval to initiate a Phase I/II human clinical trial designed to enroll up to 30 healthy volunteers to demonstrate the bioequivalence of safflower-produced insulin to comparator insulin products. After discussions with the FDA in late 2006, SemBioSys was informed that safflower-produced insulin is eligible to receive approval through an abbreviated 505(b)(2) regulatory path. The European authorities have already published guidance documents concerning the approval of human insulin which are consistent with this approach.

The world market for insulin is estimated to be in excess of US$7.1 billion today and the demand for insulin is projected to increase due to two factors: demographic and dietary choices in the western world are causing an increase in the incidence of diabetes; and at the same time, countries in the rest of the world that are currently underserved in the insulin market, are demanding greater access to insulin at an affordable price. By 2012, independent estimates predict a US$15 billion insulin market. SemBioSys' plant-made insulin is expected to offer capital and operating cost reductions with the potential to enter the market as a low-cost, easily expandable source of insulin to meet this exploding demand.

About SemBioSys Genetics Inc.

Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AIMilano, a next generation cardiovascular drug. In addition to its pharmaceutical products, SemBioSys and its subsidiary, Botaneco Specialty Ingredients Inc., are developing a series of non-pharmaceutical products addressing human topical, nutritional oils and agricultural biotechnology markets. More i
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SemBioSys updates Apo AI development program
2. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
3. SemBioSys announces 2007 third quarter results
4. SemBioSys signs option agreement for safflower-produced food ingredient
5. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
6. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
7. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
8. SemBioSys announces 2007 financial and operational results
9. SemBioSys initiates toxicology study for safflower-produced insulin
10. SemBioSys receives milestone payments from AVAC Ltd.
11. SemBioSys announces first quarter 2008 financial and operational results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a ... release its full financial results for the fourth quarter and ... after market close, followed by a conference call at ... outlook. Participants should call (888) 243-4451 ( ... the InspireMD call. A live webcast of the call will ...
(Date:3/6/2015)... According to a new market ... patch, Allograft, Xenograft, Suture Anchor, Interference Screws, Laparoscopic Instruments) ... augmentation) - Global Forecast to 2019", published by MarketsandMarkets, ... $14.7 Billion in 2019 from $10.3 Billion in 2014, ... 2019. Browse 70 market data tables ...
(Date:3/6/2015)... 06, 2015 AACC International unveiled ... for the grain scientists’ Centennial Meeting and also ... 2015 marks the 100th anniversary of AACC International ... Minneapolis, Minnesota, U.S.A. on October 18-21, 2015. The ... who are looking to the next 100 years ...
(Date:3/6/2015)... 6, 2015  Attorney Advertising-- Bronstein, Gewirtz & Grossman, ... purchasers of the securities of Orexigen Therapeutics, Inc. ... -News).  Such investors are advised to contact ... coordinator Eitan Kimelman at info@bgandg.com ... whether Orexigen and certain of its officers and/or ...
Breaking Biology Technology:InspireMD to Report Financial Results for the Fourth Quarter and Year Ended December 31, 2014 on Thursday, March 12th 2Soft Tissue Repair Market worth $14.7 Billion in 2019 2Soft Tissue Repair Market worth $14.7 Billion in 2019 3Soft Tissue Repair Market worth $14.7 Billion in 2019 4AACCI Unveils Scientific Symposia Sessions for Centennial Meeting 2SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Orexigen Therapeutics, Inc. 2
... , May 17 Sigma-Aldrich Corporation (Nasdaq: SIAL ) will ... 20th at 1:15 PM CDT ( 2:15 PM EDT ) ... over the Internet available at http://investor.sigmaaldrich.com/ .  Users can click the "Webcast" ... , , ...
... May 17 TriReme Medical, Inc. (TMI) announced today that ... for its GliderXtreme™ PTA balloon catheter. GliderXtreme™ is now approved for ... balloon diameters from 2.0 – 5.0mm and in balloon lengths up ... , ...
... 17 ViroPharma Incorporated (Nasdaq: VPHM ) today ... Cinryze™ (C1 Esterase Inhibitor [Human]) in preventing and treating attacks ... Health,s online clinical trial registry, www.clinicaltrials.gov . The data ... data from the CHANGE 2 acute treatment study will be ...
Cached Biology Technology:Sigma-Aldrich Corporation to Present at the Baird's 2010 Growth Stock Conference on Thursday, May 20, 2010 2TriReme Medical, Inc. Receives FDA 510(k) Clearance for a Broad Matrix of GliderXtreme(TM) PTA Balloon Catheter Sizes 2ViroPharma Announces Availability of Cinryze(TM) (C1 Esterase Inhibitor [Human]) Final Open-Label Data 2ViroPharma Announces Availability of Cinryze(TM) (C1 Esterase Inhibitor [Human]) Final Open-Label Data 3ViroPharma Announces Availability of Cinryze(TM) (C1 Esterase Inhibitor [Human]) Final Open-Label Data 4ViroPharma Announces Availability of Cinryze(TM) (C1 Esterase Inhibitor [Human]) Final Open-Label Data 5ViroPharma Announces Availability of Cinryze(TM) (C1 Esterase Inhibitor [Human]) Final Open-Label Data 6ViroPharma Announces Availability of Cinryze(TM) (C1 Esterase Inhibitor [Human]) Final Open-Label Data 7
(Date:3/5/2015)... 5, 2015 In Brazil , ... already using these solutions and 42 percent planning to invest ... approximately 25 percent of the companies will be investing in ... majority of companies in the region are currently opting for ... model will command significant attention in the coming years. This ...
(Date:3/4/2015)... Mar. 04, 2015 Research and Markets ... of the "Global Biometrics Market Forecast and ... The market for biometric authentication systems is ... 14% till 2020 The driving forces ... security needs, government projects and constant development in ...
(Date:3/3/2015)... , March 3, 2015 ... provider of advanced cryogenic logistics solutions for ... immunotherapies, stem cells, cell lines, clinical research ... medicine, today announced the expansion of its ... Centers, ("Fred Hutch") Clinical Research Division ...
Breaking Biology News(10 mins):Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... the University of Leicester has proposed an immense (1.5km) exhibition ... a vivid perspective of how quickly human activity is changing ... at a rate of a few centimetres every thousand years. ... vertically down into the sea bed to extract a sample ...
... 1 The U.S. Department of Homeland,Security ... collecting additional,fingerprints from international visitors arriving at ... change is part of the,department,s upgrade from ... facilitate legitimate travel by more accurately and,efficiently ...
... Mouse and rat brain atlases have long ... traditional brain atlases offer an incomplete map ... Reference Atlas: A Digital Color Brain Atlas ... Edition; January 2008; $195.00; 376 Pages; Paperback; ...
Cached Biology News:DHS Begins Collecting 10 Fingerprints From International Visitors at George Bush Houston Intercontinental Airport 2Book is the first high-resolution digital mouse brain atlas designed for Web applications 2
Mouse polyclonal antibody to PRDM2 - PR domain containing 2, with ZNF domain...
Hepatocyte Differentiation Environment...
Mouse monoclonal [M2II-12] to MRP2 ( Abpromise for all tested applications). entrezGeneID: 1244 SwissProtID: Q92887...
...
Biology Products: